CDK4 and breast cancer: In 2015, Palbociclib was the first CDK 4/6 inhibitor (6) to be approved by the FDA, [18] and shortly after, the CDK4/6 inhibitors ribociclib (7) [19] and abemaciclib (8) [20] also received FDA approval for the treatment of breast cancer.